Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sulbentine
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Sulbentine (also known as dibenzthione) is an azole antifungal agent with both fungistatic and fungicidal activity. It is primarily used as a locally acting antimycotic, especially for the treatment of dermatomycoses (fungal infections of the skin). Sulbentine belongs to the class of benzylamines and has a broad spectrum effect against various fungal pathogens. Its mechanism involves disruption of fungal cell growth, though specific molecular targets are not well characterized in public sources. The drug has reached up to Phase II clinical trials and is classified under ATC code D01AE09[1][2][3][4][5].
- Other names
- sulbentinedibenzthione
Beyond the preview
Go deeper on sulbentine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sulbentine.